Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype

R. Suzuki, Y. Kagami, K. Takeuchi, M. Kami, M. Okamoto, R. Ichinohasama, N. Mori, M. Kojima, Tadashi Yoshino, H. Yamabe, M. Shiota, S. Mori, M. Ogura, N. Hamajima, M. Seto, T. Suchi, Y. Morishima, S. Nakamura

Research output: Contribution to journalArticle

134 Citations (Scopus)

Abstract

Anaplastic large cell lymphoma (ALCL) is a distinct entity of non-Hodgkin lymphoma, characterized by a proliferation of pleomorphic large lymphoid cells that express CD30. Recent studies have found that a subset of ALCL aberrantly expresses a chimeric anaplastic lymphoma kinase (ALK) protein as a result of t(2; 5)(p23;q35) or variant translocations. ALK-positive ALCLs feature good prognosis, but some of them lead to poor outcomes. Since CD56 is expressed in some ALCLs, its clinical significance was examined in a series of T/null cell type ALCLs. Of 143 patients, 83 (58%) showed ALK-positive staining, and of 140 patients, 25 (18%) expressed CD56. The ALK-positive subgroup was characterized by a younger age of onset (P <.0001), lower serum lactate dehydrogenase level (P = .01), better performance status (P = .03), less frequent extranodal involvement (P = .01), lower international prognostic index (IPI) categories (P = .002), and superior survival (P = .0009) in comparison with the ALK-negative group, suggesting that ALK is a specific marker defining a distinct subtype. CD56+ cases showed a significantly poor prognosis overall (P = .002) as well as in both ALK-positive and ALK-negative subgroups (P = .02 and P = .04, respectively). Multivariate analysis confirmed that CD56 is independent of other prognostic factors, including IPI. Although CD56+ cases showed a higher incidence of bone involvement, no other differences in clinicopathologic parameters were found between the CD56+ and CD56- groups. These findings suggest that CD56 is not a marker to identify a distinct subtype of ALCL, but a strong clinical prognostic factor. Effective therapeutic approaches should be explored for high-risk ALCL patients, who can be identified by means of a prognostic model, including CD56. (C) 2000 by The American Society of Hematology.

Original languageEnglish
Pages (from-to)2993-3000
Number of pages8
JournalBlood
Volume96
Issue number9
Publication statusPublished - Nov 1 2000
Externally publishedYes

Fingerprint

Anaplastic Large-Cell Lymphoma
Null Lymphocytes
Phenotype
anaplastic lymphoma kinase
Age of Onset
L-Lactate Dehydrogenase
Non-Hodgkin's Lymphoma
Bone
Multivariate Analysis
Lymphocytes
Staining and Labeling
Bone and Bones
Survival
Incidence

ASJC Scopus subject areas

  • Hematology

Cite this

Suzuki, R., Kagami, Y., Takeuchi, K., Kami, M., Okamoto, M., Ichinohasama, R., ... Nakamura, S. (2000). Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype. Blood, 96(9), 2993-3000.

Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype. / Suzuki, R.; Kagami, Y.; Takeuchi, K.; Kami, M.; Okamoto, M.; Ichinohasama, R.; Mori, N.; Kojima, M.; Yoshino, Tadashi; Yamabe, H.; Shiota, M.; Mori, S.; Ogura, M.; Hamajima, N.; Seto, M.; Suchi, T.; Morishima, Y.; Nakamura, S.

In: Blood, Vol. 96, No. 9, 01.11.2000, p. 2993-3000.

Research output: Contribution to journalArticle

Suzuki, R, Kagami, Y, Takeuchi, K, Kami, M, Okamoto, M, Ichinohasama, R, Mori, N, Kojima, M, Yoshino, T, Yamabe, H, Shiota, M, Mori, S, Ogura, M, Hamajima, N, Seto, M, Suchi, T, Morishima, Y & Nakamura, S 2000, 'Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype', Blood, vol. 96, no. 9, pp. 2993-3000.
Suzuki R, Kagami Y, Takeuchi K, Kami M, Okamoto M, Ichinohasama R et al. Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype. Blood. 2000 Nov 1;96(9):2993-3000.
Suzuki, R. ; Kagami, Y. ; Takeuchi, K. ; Kami, M. ; Okamoto, M. ; Ichinohasama, R. ; Mori, N. ; Kojima, M. ; Yoshino, Tadashi ; Yamabe, H. ; Shiota, M. ; Mori, S. ; Ogura, M. ; Hamajima, N. ; Seto, M. ; Suchi, T. ; Morishima, Y. ; Nakamura, S. / Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype. In: Blood. 2000 ; Vol. 96, No. 9. pp. 2993-3000.
@article{86181e3cab7045e48a09c88474c53cd1,
title = "Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype",
abstract = "Anaplastic large cell lymphoma (ALCL) is a distinct entity of non-Hodgkin lymphoma, characterized by a proliferation of pleomorphic large lymphoid cells that express CD30. Recent studies have found that a subset of ALCL aberrantly expresses a chimeric anaplastic lymphoma kinase (ALK) protein as a result of t(2; 5)(p23;q35) or variant translocations. ALK-positive ALCLs feature good prognosis, but some of them lead to poor outcomes. Since CD56 is expressed in some ALCLs, its clinical significance was examined in a series of T/null cell type ALCLs. Of 143 patients, 83 (58{\%}) showed ALK-positive staining, and of 140 patients, 25 (18{\%}) expressed CD56. The ALK-positive subgroup was characterized by a younger age of onset (P <.0001), lower serum lactate dehydrogenase level (P = .01), better performance status (P = .03), less frequent extranodal involvement (P = .01), lower international prognostic index (IPI) categories (P = .002), and superior survival (P = .0009) in comparison with the ALK-negative group, suggesting that ALK is a specific marker defining a distinct subtype. CD56+ cases showed a significantly poor prognosis overall (P = .002) as well as in both ALK-positive and ALK-negative subgroups (P = .02 and P = .04, respectively). Multivariate analysis confirmed that CD56 is independent of other prognostic factors, including IPI. Although CD56+ cases showed a higher incidence of bone involvement, no other differences in clinicopathologic parameters were found between the CD56+ and CD56- groups. These findings suggest that CD56 is not a marker to identify a distinct subtype of ALCL, but a strong clinical prognostic factor. Effective therapeutic approaches should be explored for high-risk ALCL patients, who can be identified by means of a prognostic model, including CD56. (C) 2000 by The American Society of Hematology.",
author = "R. Suzuki and Y. Kagami and K. Takeuchi and M. Kami and M. Okamoto and R. Ichinohasama and N. Mori and M. Kojima and Tadashi Yoshino and H. Yamabe and M. Shiota and S. Mori and M. Ogura and N. Hamajima and M. Seto and T. Suchi and Y. Morishima and S. Nakamura",
year = "2000",
month = "11",
day = "1",
language = "English",
volume = "96",
pages = "2993--3000",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "9",

}

TY - JOUR

T1 - Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype

AU - Suzuki, R.

AU - Kagami, Y.

AU - Takeuchi, K.

AU - Kami, M.

AU - Okamoto, M.

AU - Ichinohasama, R.

AU - Mori, N.

AU - Kojima, M.

AU - Yoshino, Tadashi

AU - Yamabe, H.

AU - Shiota, M.

AU - Mori, S.

AU - Ogura, M.

AU - Hamajima, N.

AU - Seto, M.

AU - Suchi, T.

AU - Morishima, Y.

AU - Nakamura, S.

PY - 2000/11/1

Y1 - 2000/11/1

N2 - Anaplastic large cell lymphoma (ALCL) is a distinct entity of non-Hodgkin lymphoma, characterized by a proliferation of pleomorphic large lymphoid cells that express CD30. Recent studies have found that a subset of ALCL aberrantly expresses a chimeric anaplastic lymphoma kinase (ALK) protein as a result of t(2; 5)(p23;q35) or variant translocations. ALK-positive ALCLs feature good prognosis, but some of them lead to poor outcomes. Since CD56 is expressed in some ALCLs, its clinical significance was examined in a series of T/null cell type ALCLs. Of 143 patients, 83 (58%) showed ALK-positive staining, and of 140 patients, 25 (18%) expressed CD56. The ALK-positive subgroup was characterized by a younger age of onset (P <.0001), lower serum lactate dehydrogenase level (P = .01), better performance status (P = .03), less frequent extranodal involvement (P = .01), lower international prognostic index (IPI) categories (P = .002), and superior survival (P = .0009) in comparison with the ALK-negative group, suggesting that ALK is a specific marker defining a distinct subtype. CD56+ cases showed a significantly poor prognosis overall (P = .002) as well as in both ALK-positive and ALK-negative subgroups (P = .02 and P = .04, respectively). Multivariate analysis confirmed that CD56 is independent of other prognostic factors, including IPI. Although CD56+ cases showed a higher incidence of bone involvement, no other differences in clinicopathologic parameters were found between the CD56+ and CD56- groups. These findings suggest that CD56 is not a marker to identify a distinct subtype of ALCL, but a strong clinical prognostic factor. Effective therapeutic approaches should be explored for high-risk ALCL patients, who can be identified by means of a prognostic model, including CD56. (C) 2000 by The American Society of Hematology.

AB - Anaplastic large cell lymphoma (ALCL) is a distinct entity of non-Hodgkin lymphoma, characterized by a proliferation of pleomorphic large lymphoid cells that express CD30. Recent studies have found that a subset of ALCL aberrantly expresses a chimeric anaplastic lymphoma kinase (ALK) protein as a result of t(2; 5)(p23;q35) or variant translocations. ALK-positive ALCLs feature good prognosis, but some of them lead to poor outcomes. Since CD56 is expressed in some ALCLs, its clinical significance was examined in a series of T/null cell type ALCLs. Of 143 patients, 83 (58%) showed ALK-positive staining, and of 140 patients, 25 (18%) expressed CD56. The ALK-positive subgroup was characterized by a younger age of onset (P <.0001), lower serum lactate dehydrogenase level (P = .01), better performance status (P = .03), less frequent extranodal involvement (P = .01), lower international prognostic index (IPI) categories (P = .002), and superior survival (P = .0009) in comparison with the ALK-negative group, suggesting that ALK is a specific marker defining a distinct subtype. CD56+ cases showed a significantly poor prognosis overall (P = .002) as well as in both ALK-positive and ALK-negative subgroups (P = .02 and P = .04, respectively). Multivariate analysis confirmed that CD56 is independent of other prognostic factors, including IPI. Although CD56+ cases showed a higher incidence of bone involvement, no other differences in clinicopathologic parameters were found between the CD56+ and CD56- groups. These findings suggest that CD56 is not a marker to identify a distinct subtype of ALCL, but a strong clinical prognostic factor. Effective therapeutic approaches should be explored for high-risk ALCL patients, who can be identified by means of a prognostic model, including CD56. (C) 2000 by The American Society of Hematology.

UR - http://www.scopus.com/inward/record.url?scp=0034329288&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034329288&partnerID=8YFLogxK

M3 - Article

C2 - 11049976

AN - SCOPUS:0034329288

VL - 96

SP - 2993

EP - 3000

JO - Blood

JF - Blood

SN - 0006-4971

IS - 9

ER -